ChangChun High New Technology Industries operates within the Medicinals and botanicals sector.
In addition to historical fundamental analyses, the complete report available to purchase compares ChangChun High New Technology Industries with three other
companies in this sector in China:
Shenzhen Hepalink Pharmaceutical Company Limited
sales of 2.29 billion Chinese Renmimbi [US$334.01 million]
of which 100%
was Pharmaceutical Manufacturing),
Shanxi Zhendong Pharmaceutical Co Ltd
(2.26 billion Chinese Renmimbi [US$329.97 million]
of which 95%
was Medicine Manufacture and Sale), and
Shandong Lukang Pharmaceutical
(2.41 billion Chinese Renmimbi [US$351.46 million]
of which 71%
was Human Antibiotic).
During the year ended December of 2015, sales at
ChangChun High New Technology Industries were 2.37 billion Chinese Renmimbi (US$346.42 million).
increase of 6.3%
versus 2014, when the company's sales were 2.23 billion Chinese Renmimbi.
This was the fifth consecutive year of sales increases at ChangChun High New Technology Industries
(and since 2010, sales have increased a total of 104%).
Sales of Medication saw an increase
7.2% in 2015, from
1.76 billion Chinese Renmimbi to 1.89 billion Chinese Renmimbi.